Clinical trial
Precision Therapy for Solid Tumors: Synergistic Inhibition of Cell Proliferation and Angiogenesis Via CDK4/6 and Anti-VEGF Approach Targeting LncRNA Expression
NCT06307249 is registered in ClinicalTrials.gov with Lebanese University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Precision Therapy for Solid Tumors: Synergistic Inhibition of Cell Proliferation and Angiogenesis Via CDK4/6 and Anti-VEGF Approach Targeting LncRNA Expression
- Lead sponsor
- Lebanese University
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 15, 2023
- Completion date
- December 31, 2027
- Enrollment
- 50 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, cancer, chemotherapy, colorectal cancer, immunotherapy, lung cancer, ovarian cancer, precision therapy, solid tumor, targeted therapy